<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00606515</url>
  </required_header>
  <id_info>
    <org_study_id>LPS-PK-01-2008</org_study_id>
    <nct_id>NCT00606515</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics Study of Liposomal Paclitaxel in Humans</brief_title>
  <acronym>LPS-PK-H</acronym>
  <official_title>A Clinical Trial to Compare the Pharmacokinetics of Two Formulations of Taxane, Paclitaxel Injection and Liposomal Paclitaxel, in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shandong Luye Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nanjing Sike Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong Luye Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether there is any difference of the
      pharmacokinetics of two taxane formulations, paclitaxel injection and liposomal paclitaxel in
      Chinese cancer patients with solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetics of a new formulation of taxane (liposomal paclitaxel) has never been
      studied in Chinese cancer patients. This clinical trial is designed to find out the
      pharmacokinetics of liposomal paclitaxel at the dose of 175mg/m2 and whether it has a
      different pharmacokinetic profile to paclitaxel.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic parameters</measure>
    <time_frame>72 hours after the infusion</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">16</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Liposomal paclitaxel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liposomal paclitaxel</intervention_name>
    <description>Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.</description>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <description>Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.</description>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Eligible patients must have histologically confirmed solid tumors of advanced stages

          -  Patients who are suitable for being treated with liposomal paclitaxel only

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2

          -  Patients who are expected to be alive for at least 3 months

          -  Adequate hematologic, hepatic and renal functions

          -  Adequate other organ functions as defined by the protocol

          -  No prior systemic chemotherapy at least 4 weeks before the recruitment

          -  No previous anaphylactic reaction to hormone.

        Exclusion Criteria:

          -  Allergy to any study medication

          -  Serious complication that would compromise the patient's ability to complete the study

          -  Grade â‰¥1 neuropathy using NCI CTCAE version 3.0 criteria

          -  Pregnancy or breast feeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin Li, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Hospital of Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Hospital of Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 21, 2008</study_first_submitted>
  <study_first_submitted_qc>January 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2008</study_first_posted>
  <last_update_submitted>February 9, 2009</last_update_submitted>
  <last_update_submitted_qc>February 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Dr. Li Jin</name_title>
    <organization>Cancer Hospital of Fudan University</organization>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Liposomal paclitaxel</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 14, 2009</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>April 20, 2009</submitted>
    <returned>June 9, 2009</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

